Search Patents
  • Covid-19 spike-ACE2 binding assay for drug and antibody screening
    Patent number: 11249083
    Abstract: The present disclosure an ELISA-based assay that uses a glycosylated polypeptide fragment derived from the SARS-CoV-2 spike protein (Covid-19) receptor binding domain (S1RBD) that has affinity for the extracellular domain of Angiotensin Converting Enzyme 2 (ACE2). The S1RBD polypeptide is generated by expression of an encoding nucleic acid by a human cell expression system resulting in glycosylation of the expressed spike receptor binding domain (S1RBD) protein at least at the N343 N-glycosylation site thereof, and which surprisingly and significantly increases the affinity of the S1RBD for ACE2, provides a significant increase in the sensitivity of the assay compared to other known assays.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: February 15, 2022
    Assignee: RayBiotech Life, Inc.
    Inventors: Ruo-Pan Huang, Hao Tang, Shuhong Luo, Jianmin Fang
  • Method And System For Virus And Protein-Antibody Interactions Detection And Monitoring Based On Optical Light Intensity And Electrical Parameters
    Publication number: 20220018839
    Abstract: A novel method of detecting and destroying viral transmissions such as SARS-CoV-2 transmission is described. The proposed technique uses a light source such as that from a smart phone and a mobile spectrophotometer to enable detection of proteins in solution. The technique allows for detecting soluble preparations of for example spike protein subunits from SARS-CoV-2, followed by detection of the actual binding potential of the spike protein with its host receptor, for example the angiotensin-converting enzyme 2 (ACE2) or other antigens or elements. The results are validated by showing that this method can detect antigen-antibody binding using two independent protein-antibody pairs. Finally, this technique is combined with DC bias to show that introduction of a current in the system can be used to disrupt the antigen-antibody reaction, suggesting that this technique can be a powerful means of disrupting virus transmission by destroying virus-receptor interactions.
    Type: Application
    Filed: July 19, 2021
    Publication date: January 20, 2022
    Inventors: Mahmoud F.Y. Al Ahmad, Tahir A. Rizvi, Farah Mustafa
  • NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USES
    Publication number: 20210347835
    Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 11, 2021
    Inventors: Patrick AMSTUTZ, Valerie Perrine CALABRO, Marcel WALSER
  • Method and system for virus and protein-antibody interactions detection and monitoring based on optical light intensity and electrical parameters
    Patent number: 11493514
    Abstract: A novel method of detecting and destroying viral transmissions such as SARS-CoV-2 transmission is described. The proposed technique uses a light source such as that from a smart phone and a mobile spectrophotometer to enable detection of proteins in solution. The technique allows for detecting soluble preparations of for example spike protein subunits from SARS-CoV-2, followed by detection of the actual binding potential of the spike protein with its host receptor, for example the angiotensin-converting enzyme 2 (ACE2) or other antigens or elements. The results are validated by showing that this method can detect antigen-antibody binding using two independent protein-antibody pairs. Finally, this technique is combined with DC bias to show that introduction of a current in the system can be used to disrupt the antigen-antibody reaction, suggesting that this technique can be a powerful means of disrupting virus transmission by destroying virus-receptor interactions.
    Type: Grant
    Filed: July 19, 2021
    Date of Patent: November 8, 2022
    Assignee: United Arab Emirates University
    Inventors: Mahmoud F. Y. Al Ahmad, Tahir A. Rizvi, Farah Mustafa
  • PROTEIN MICROARRAY, DETECTION METHOD THEREOF AND EVALUATION METHOD THEREOF
    Publication number: 20220170923
    Abstract: A protein microarray, a detection method thereof, and an evaluation method thereof are provided. The protein microarray includes a carrier including a protein array block on a surface thereof and at least one protein immobilized on the protein array block. The at least one protein includes a spike protein and a nucleocapsid protein, and can bind to a first antibody in a to-be-tested sample. A method for detecting virus infection or evaluating the ability of a bioagent to block virus infection includes the steps of respectively adding blood, serum, plasma or the bioagent and a second antibody to the protein microarray and detecting an optical signal. The protein microarray can be used to detect a coronavirus and an influenza virus, and achieve the effect of quickly, sensitively, and accurately confirming whether a subject is infected by the virus.
    Type: Application
    Filed: January 4, 2021
    Publication date: June 2, 2022
    Applicant: NATIONAL CHENG KUNG UNIVERSITY
    Inventor: Guan-Da SYU
  • NOVEL ANKYRIN REPEAT BINDING PROTEINS AND THEIR USES
    Publication number: 20220235103
    Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
    Type: Application
    Filed: February 11, 2022
    Publication date: July 28, 2022
    Inventors: Patrick AMSTUTZ, Valerie Perrine CALABRO, Marcel WALSER
  • Methods for Treating or Preventing SARS-CoV-2 Infections and COVID-19 with Anti-SARS-CoV-2 Spike Glycoprotein Antibodies
    Publication number: 20210395345
    Abstract: The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).
    Type: Application
    Filed: June 2, 2021
    Publication date: December 23, 2021
    Inventors: Samit Ganguly, Jennifer Hamilton, Gary Herman, Andrea Hooper, Flonza Isa, Meagan O'Brien, Sumathi Sivapalasingam, Kenneth Turner, Eduardo Forleo Neto
  • PHAGE RECEPTOR BINDING PROTEINS FOR ANTIBACTERIAL THERAPY AND OTHER NOVEL USES
    Publication number: 20110143997
    Abstract: The subject invention relates in part to novel uses of bacteriophage tail spike proteins (TSPs). Some preferred uses are therapeutic uses in animals, such as chickens, against pathogenic bacteria, such as Salmonella. Fragments of the TSPs can also be used according to the subject invention, particularly protein fragments comprising the phage receptor binding domains (PRBDs), which recognize their hosts and facilitate infection. The binding domains are specific to unique surface structures on bacteria and may be used for a variety of applications according to the subject invention. We have shown that by utilizing these PRBDs, it is possible to exploit the long-established evolutionary relationship between bacteria and their viruses (ie bacteriophages) that specifically infect them. The subject invention also relates in part to novel, synthetic forms of tail spike proteins. In some preferred embodiments, these are hexamers.
    Type: Application
    Filed: March 28, 2008
    Publication date: June 16, 2011
    Applicants: Dow AgroSciences LLC, National Research Council of Canada
    Inventors: Matthew J. Henry, Roger C. Mackenzie, Christine Szymanski, Jamshid Tanha
  • PROTEIN MICROARRAY, USE AND DETECTION METHOD THEREOF
    Publication number: 20230266309
    Abstract: A protein microarray, a use thereof, and a detection method thereof are provided. The protein microarray includes a carrier with a protein array block on a surface thereof and at least two kinds of proteins immobilized on the protein array block. The at least two kinds of proteins include an extracellular region or a receptor binding region of the spike protein of a virus or a variant thereof. The protein microarray can detect the protective efficacy of vaccines, antibody drugs, or small molecule drugs against viral infection, or detect the immune response of an individual after vaccination or infection with a variant strain of the virus. The detection method of protein microarray includes the steps of adding the serum, a first fluorescent labeled human angiotensin converting enzyme 2, and a second fluorescent labeled anti-human immunoglobulin antibody to the protein microarray array and detecting optical signals.
    Type: Application
    Filed: November 11, 2022
    Publication date: August 24, 2023
    Applicant: NATIONAL CHENG KUNG UNIVERSITY
    Inventor: Guan-da Syu
  • COMPOSITION FOR INHIBITING BINDING OF SARS-CoV-2 TO ACE2 PROTEIN
    Publication number: 20230126569
    Abstract: The present invention searches for compounds etc. that may inhibit the interaction between the spike (S) protein of SARS-CoV-2 and the ACE2 protein. The present invention provides a composition for inhibiting the binding between the spike (S) protein of SARS-CoV-2 and the angiotensin converting enzyme 2 (ACE2) protein comprising an effective amount of chlorine dioxide.
    Type: Application
    Filed: March 3, 2021
    Publication date: April 27, 2023
    Inventors: Norio Ogata, Takanori Miura
  • Ankyrin repeat binding proteins and their uses
    Patent number: 11466062
    Abstract: The present invention relates to recombinant binding proteins comprising one or more designed ankyrin repeat domains with binding specificity for coronavirus spike proteins, nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such proteins, nucleic acids or pharmaceutical compositions in the treatment of coronavirus diseases, particularly diseases caused by SARS-CoV-2.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: October 11, 2022
    Assignee: MOLECULAR PARTNERS AG
    Inventors: Patrick Amstutz, Valerie Perrine Calabro, Marcel Walser
  • IMPROVED METHODS OF PRODUCING A LIPIDATED PROTEIN
    Publication number: 20240026412
    Abstract: The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.G5) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).
    Type: Application
    Filed: April 9, 2021
    Publication date: January 25, 2024
    Applicant: Valneva Austria GmbH
    Inventors: Robert Schlegl, Franz Moisi, Markus Hanner, Urban Lundberg
  • Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
    Publication number: 20240043504
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Application
    Filed: May 26, 2021
    Publication date: February 8, 2024
    Inventors: Alina Baum, Benjamin Fulton, Christos Kyratsous, George D. Yancopoulos
  • Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
    Patent number: 11857620
    Abstract: Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: January 2, 2024
    Assignee: ImmunityBio, Inc.
    Inventors: Patrick Soon-Shiong, Peter Sieling, Kayvan Niazi, Shahrooz Rabizadeh, Lise Geissert, Annie Shin, Adrian Rice, Elizabeth Gabitzsch, Jeffrey Safrit, Leonard Sender
  • Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
    Publication number: 20230125469
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
    Type: Application
    Filed: July 13, 2022
    Publication date: April 27, 2023
    Inventors: Alina BAUM, Christos KYRATSOUS, George D. YANCOPOULOS
  • ACE2-Fc FUSION PROTEINS FOR SARS-COV-2 MITIGATION
    Publication number: 20220002699
    Abstract: The present disclosure relates to recombinant fusion proteins comprising an extracellular domain of the human angiotensin-converting enzyme 2 (ACE2), optionally having altered amino acid residues that result in increased binding affinity for the S1 spike protein of SARS-CoV-2, linked to a human immunoglobulin Fc region, that can extend the protein half-life (T1/2) and/or the duration of action as a decoy receptor, and compositions and methods of use of these fusion proteins.
    Type: Application
    Filed: March 7, 2021
    Publication date: January 6, 2022
    Applicant: PLANET BIOTECHNOLOGY, INC.
    Inventors: Keith Lynn WYCOFF, Y TRAN
  • IMPROVED CORONAVIRUS VACCINE
    Publication number: 20240016917
    Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.
    Type: Application
    Filed: April 12, 2022
    Publication date: January 18, 2024
    Inventors: Che MA, Chi-Huey WONG, Han-Yi HUANG
  • PEPTIDE FOR SUPPRESSING CORONAVIRUS AND USE THEREOF
    Publication number: 20230181681
    Abstract: The present invention relates to: a therapeutic composition for coronavirus comprising, as an active ingredient, one peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 6, and SEQ ID NO: 8 that binds to a coronavirus N-protein, a coronavirus-derived spike protein, or a fragment of the spike protein; and a composition that binds to a coronavirus N-protein comprising, as an active ingredient, the coronavirus-derived spike protein or the fragment of the spike protein. It is suggested that the peptides of the present invention, based on the understanding and targeting of the interaction of the coronavirus S protein and N protein of the present invention, have an effect that can be helpful in the treatment of coronaviruses including MERS-CoV, SARS-CoV-2, SARS-CoV, and HCoV-OC43.
    Type: Application
    Filed: May 3, 2021
    Publication date: June 15, 2023
    Inventors: Hyung Joo KWON, Byoung Kwon PARK, Dong Bum KIM, Jin Soo KIM
  • ENGINEERING CORONAVIRUS SPIKE PROTEINS AS VACCINE ANTIGENS, THEIR DESIGN AND USES
    Publication number: 20230226170
    Abstract: A vaccine for preventing CoV infection includes at least one DNA, RNA or protein sequence for S protein with at least one modification which is a full deletion or partial deletion of the SI region or a partial or full replacement of the SI region. A method of vaccinating a mammal subject against infection from at least one group of CoV includes separating a broad group of CoV into homology groups, creating a modified S protein containing at least one modification at its S1 region, and identifying at least one consensus sequence for each homology group which has a sequence identity of greater than 60% to all other members of the homology group. The consensus sequence is a protein sequence for the modified S protein, a DNA sequence encoding the modified S protein, and an RNA sequence encoding the modified S protein.
    Type: Application
    Filed: May 12, 2021
    Publication date: July 20, 2023
    Inventors: Uwe D. STAERZ, Daniel F. PRESTON, Yan QI
  • RECOMBINANT PROTEIN AND VACCINE COMPOSITION OF PORCINE EPIDEMIC DIARRHEA VIRUS
    Publication number: 20220370597
    Abstract: A recombinant protein and a vaccine composition for porcine epidemic diarrhea (PED) are provided. The recombinant protein is a fusion protein formed by connecting the truncated segment of S protein (Spike protein) from porcine epidemic diarrhea virus (PEDV) in tandem with the Fc fragment of porcine IgG, and the truncated fragment of S protein is preferably selected from N-terminal domain (NTD) with sialic acid binding activity in S1 subunit of S protein, neutralizing epitope domain (COE) and multiple B-cell epitopes in S2 subunit; the vaccine composition contains recombinant protein and adjuvants. The recombinant protein of the application can produce IgG antibody and neutralizing antibody titers of rather high level after immunizing mice, and the proportions of CD3+CD4+, CD3+CD8+ lymphocytes and the concentrations of IFN-? and IL-4 in lymphocytes are significantly increased.
    Type: Application
    Filed: January 27, 2022
    Publication date: November 24, 2022
    Inventors: Bin Li, Baochao Fan, Danyi Shi, Jinzhu Zhou, Rongli Guo, Kongwang He, Yongxiang Zhao, Xuejiao Zhu, Li Li, Wei Wang, Dandan Wang, Haodan Zhu
Narrow Results

Filter by US Classification